Clovis Oncology, Inc. (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $91.56, for a total value of $274,680.00. Following the transaction, the insider now directly owns 197,583 shares in the company, valued at approximately $18,090,699.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Clovis Oncology, Inc. (CLVS) traded down 2.93% during trading on Monday, hitting $88.87. The stock had a trading volume of 1,595,306 shares. Clovis Oncology, Inc. has a one year low of $13.43 and a one year high of $96.92. The company’s market cap is $3.98 billion. The firm has a 50 day moving average of $64.85 and a 200-day moving average of $58.78.

Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.43) by $0.10. The company had revenue of $7.05 million for the quarter, compared to analyst estimates of $6.04 million. Equities analysts anticipate that Clovis Oncology, Inc. will post ($5.66) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/17/clovis-oncology-inc-nasdaqclvs-insider-gillian-c-ivers-read-sells-3000-shares.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. boosted its position in Clovis Oncology by 20.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,400 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the last quarter. First Mercantile Trust Co. bought a new position in Clovis Oncology during the first quarter valued at approximately $115,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Clovis Oncology by 71.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 758 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Clovis Oncology by 3.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 100 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Clovis Oncology during the first quarter valued at approximately $185,000. 89.68% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on CLVS. Credit Suisse Group reissued an “outperform” rating and set a $74.00 target price on shares of Clovis Oncology in a research report on Tuesday, April 18th. Cann began coverage on Clovis Oncology in a research report on Thursday, June 22nd. They set a “market perform” rating on the stock. BidaskClub raised Clovis Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Zacks Investment Research downgraded Clovis Oncology from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, J P Morgan Chase & Co raised Clovis Oncology from a “neutral” rating to an “overweight” rating and set a $72.00 target price on the stock in a research report on Wednesday, May 17th. Eight research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $78.00.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.